iSpecimen gets Nasdaq extension to meet $2.5 million stockholders’ equity rule by Nov. 25

The compliance plan cites a May 11 private placement raising about $2.5 million, with a planned best-efforts public offering targeting about $5 million.

Nasdaq will keep monitoring, and the next annual filing for the year ended Dec. 31, 2026 must also show compliance to avoid delisting risk.

iSpecimen received a Nasdaq notice granting an extension to regain compliance with Listing Rule 5550(b) on minimum stockholders’ equity.

Nasdaq first flagged the deficiency on May 29, 2026; the rule requires $2.5 million equity, $35 million market value, or $500,000 net income. The deadline to evidence compliance is Nov. 25, 2026. Failure could trigger delisting proceedings, though trading continues for now.